Results 211 to 220 of about 10,738 (252)

A Comparison of Budesonide and Mesalamine for Active Crohn's Disease [PDF]

New England Journal of Medicine, 1998
Crohn's disease is often treated with glucocorticoids or mesalamine. We compared the efficacy and safety of controlled-ileal-release budesonide capsules and slow-release mesalamine tablets in patients with active Crohn's disease affecting the ileum, the ascending colon, or both.In a double-blind, multicenter trial, we enrolled 182 patients with scores ...
Antoine Cortot, Ole Østergaard Thomsen, John P. Wright, Tore Persson, Eva Pettersson, Fernando Tavarela Veloso, Trevor A. Winter, Morten H. Vatn, Derek P. Jewell   +8 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Mesalamine

Hospital Pharmacy, 2007
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Terri Levien, Dennis J. Cada, Danial E. Baker   +2 more
openaire   +2 more sources

The Association of Mesalamine With Kidney Disease

Advances in Chronic Kidney Disease, 2020
The package inserts for products containing 5-aminosalicylic acid, or mesalamine, include the following language regarding the risk of adverse kidney effects: "renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and rarely renal failure, has been reported in patients given products such as mesalamine ...
Avinash Adiga, David S. Goldfarb
openaire   +3 more sources

Mesalamine-Associated Thrombocytopenia

American Journal of Gastroenterology, 1999
We describe a case of a 25-yr-old woman with ulcerative colitis who developed marked thrombocytopenia during treatment and upon rechallenge with oral mesalamine. In contrast to its parent drug, sulfasalazine, which has often been reported to cause serious blood disorders, particularly agranulocytosis, mesalamine has rately been implicated as a cause of
Pierre Michetti, Steven N Fine, Mark A. Peppercorn, Richard J. Farrell   +3 more
openaire   +3 more sources

Mesalamine in Ulcerative Colitis

DICP, 1991
Sulfasalazine has been used for many years in the management of ulcerative colitis. As many as 20 percent of patients treated with it experience intolerable adverse effects usually attributed to its sulfapyridine component. The other active component is 5-aminosalicylic acid (5-ASA); the only 5-ASA enema preparation currently available in the U.S.
J M Fitzgerald, T D Marsh
openaire   +3 more sources